91 related articles for article (PubMed ID: 19739080)
1. Hospicells derived from ovarian cancer stroma inhibit T-cell immune responses.
Martinet L; Poupot R; Mirshahi P; Rafii A; Fournié JJ; Mirshahi M; Poupot M
Int J Cancer; 2010 May; 126(9):2143-52. PubMed ID: 19739080
[TBL] [Abstract][Full Text] [Related]
2. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis.
Pasquet M; Golzio M; Mery E; Rafii A; Benabbou N; Mirshahi P; Hennebelle I; Bourin P; Allal B; Teissie J; Mirshahi M; Couderc B
Int J Cancer; 2010 May; 126(9):2090-101. PubMed ID: 19739074
[TBL] [Abstract][Full Text] [Related]
3. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours.
Rafii A; Mirshahi P; Poupot M; Faussat AM; Simon A; Ducros E; Mery E; Couderc B; Lis R; Capdet J; Bergalet J; Querleu D; Dagonnet F; Fournié JJ; Marie JP; Pujade-Lauraine E; Favre G; Soria J; Mirshahi M
PLoS One; 2008; 3(12):e3894. PubMed ID: 19079610
[TBL] [Abstract][Full Text] [Related]
4. Oncologic trogocytosis with Hospicells induces the expression of N-cadherin by breast cancer cells.
Lis R; Capdet J; Mirshahi P; Lacroix-Triki M; Dagonnet F; Klein C; Mirshahi M; Fournié JJ; Rafii A; Poupot M
Int J Oncol; 2010 Dec; 37(6):1453-61. PubMed ID: 21042713
[TBL] [Abstract][Full Text] [Related]
5. Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages.
Castells M; Thibault B; Mery E; Golzio M; Pasquet M; Hennebelle I; Bourin P; Mirshahi M; Delord JP; Querleu D; Couderc B
Cancer Lett; 2012 Dec; 326(1):59-68. PubMed ID: 22824244
[TBL] [Abstract][Full Text] [Related]
6. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
7. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.
Kooi S; Freedman RS; Rodriguez-Villanueva J; Platsoucas CD
Lymphokine Cytokine Res; 1993 Dec; 12(6):429-37. PubMed ID: 8123759
[TBL] [Abstract][Full Text] [Related]
8. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase.
Meisel R; Brockers S; Heseler K; Degistirici O; Bülle H; Woite C; Stuhlsatz S; Schwippert W; Jäger M; Sorg R; Henschler R; Seissler J; Dilloo D; Däubener W
Leukemia; 2011 Apr; 25(4):648-54. PubMed ID: 21242993
[TBL] [Abstract][Full Text] [Related]
9. Immunopathogenesis of ovarian cancer.
Thompson MS; Mok SC
Minerva Med; 2009 Oct; 100(5):357-70. PubMed ID: 19910889
[TBL] [Abstract][Full Text] [Related]
10. CD8(+) T activation attenuates CD4(+) T proliferation through dendritic cells modification.
Chen D; Wang Y; Wang H; Wu Y; Xia S; Zhang M
Cell Immunol; 2015 Aug; 296(2):138-48. PubMed ID: 26022412
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers.
Sperner-Unterweger B; Neurauter G; Klieber M; Kurz K; Meraner V; Zeimet A; Fuchs D
Immunobiology; 2011 Mar; 216(3):296-301. PubMed ID: 20822828
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma.
Gückel B; Meyer GC; Rudy W; Batrla R; Meuer SC; Bastert G; Wallwiener D; Moebius U
Cancer Gene Ther; 1999; 6(3):228-37. PubMed ID: 10359208
[TBL] [Abstract][Full Text] [Related]
13. Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment.
Wong JL; Obermajer N; Odunsi K; Edwards RP; Kalinski P
Cancer Immunol Res; 2016 Apr; 4(4):303-11. PubMed ID: 26817996
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3 dioxygenase and regulation of T cell immunity.
Mellor A
Biochem Biophys Res Commun; 2005 Dec; 338(1):20-4. PubMed ID: 16157293
[TBL] [Abstract][Full Text] [Related]
15. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
Lambeck A; Leffers N; Hoogeboom BN; Sluiter W; Hamming I; Klip H; ten Hoor K; Esajas M; van Oven M; Drijfhout JW; Platteel I; Offringa R; Hollema H; Melief K; van der Burg S; van der Zee A; Daemen T; Nijman H
Int J Cancer; 2007 Aug; 121(3):606-14. PubMed ID: 17415711
[TBL] [Abstract][Full Text] [Related]
16. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
[TBL] [Abstract][Full Text] [Related]
17. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
Wei S; Kryczek I; Zou L; Daniel B; Cheng P; Mottram P; Curiel T; Lange A; Zou W
Cancer Res; 2005 Jun; 65(12):5020-6. PubMed ID: 15958543
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.
Kim JE; Jang MJ; Jin DH; Chung YH; Choi BS; Park GB; Kim YS; Kim S; Hur DY; Hung CF; Kim D
Int J Oncol; 2014 May; 44(5):1716-26. PubMed ID: 24573741
[TBL] [Abstract][Full Text] [Related]
19. Splenic stroma-educated regulatory dendritic cells induce apoptosis of activated CD4 T cells via Fas ligand-enhanced IFN-γ and nitric oxide.
Xu X; Yi H; Guo Z; Qian C; Xia S; Yao Y; Cao X
J Immunol; 2012 Feb; 188(3):1168-77. PubMed ID: 22205032
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
Ino K
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):13-8. PubMed ID: 20930628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
